RICT 2013<br />Drug Discovery and Selection
Conferences > Archives > RICT 2013

Confirmed Speakers


Confirmed Speakers To Date

Natural Products as Leads for Drug Discovery
Prof. Karl-Heinz ALTMANNProf. Karl-Heinz ALTMANN
(ETH ZURICH, Zurich, Switzerland)

Read more
Strategies and Challenges for the Next Generation of Therapeutic Antibodies and Derivatives
Dr Alain BECKDr Alain BECK
(PIERRE FABRE, St Julien-en-Genevois, France)

Read more
Beyond Antithrombotics: Synthetic Approaches to Unravel New Therapeutic Potentials for Glycosaminoglycans
Prof. David BONNAFFÉProf. David BONNAFFÉ
(UNIVERSITY PARIS-SUD, Orsay, France)

Read more
Systemic Safety by Design: a Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety
Dr Claire BOUIX-PETERDr Claire BOUIX-PETER
(GALDERMA R&D, Sophia-Antipolis, France)

Read more
The Discovery of Small Molecule Inhibitors of Jumonji Enzymes: Probing the Epigenome
Dr Jack BROWNDr Jack BROWN
(EPINOVA DPU, II TAU, GLAXOSMITHKLINE, Stevenage, United Kingdom)

Read more
Antibody-Drug Conjugates: A Promising new Paradigm in Cancer Therapy
Dr Ravi CHARIDr Ravi CHARI
(IMMUNOGEN, Waltham, United States)

Read more
Structure and Fragment Based Drug Design for G Protein-Coupled Receptors
Dr Miles CONGREVEDr Miles CONGREVE
(HEPTARES, Welwyn Garden City, United Kingdom)

Read more
Fragment Screening and Drug Design with Fluorine NMR Spectroscopy
Dr Claudio DALVITDr Claudio DALVIT
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)

Read more
Discovery of Highly Potent, Selective and Efficacious Cathepsin S Inhibitors
Dr Wolfgang HAAPDr Wolfgang HAAP
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Read more
Discovery and Optimization of Indoline Pyrimidone PI3Kb Inhibitors for the Treatment of PTEN-deficient Cancers
Dr Frank HALLEYDr Frank HALLEY
(SANOFI, Vitry-sur-Seine, France)

Read more
DAAO Inhibitors as Clinical Candidates
Dr Michele HEFFERNANDr Michele HEFFERNAN
(SUNOVION PHARMACEUTICALS, Marlborough, United States)

Read more
High Confidence Target and Pathway Prediction Using a Robust Chemogenomic Platform
Dr Stephen HELLIWELLDr Stephen HELLIWELL
(NOVARTIS, Basel, Switzerland)

Read more
The European Lead Factory - A Novel Discovery Partnership Model
Dr Jörg HUESERDr Jörg HUESER
(BAYER PHARMA, Wupperthal, Germany)

Read more
Targeted Cancer Chemotherapy: Developing NextGen Antibody Drug Conjugates & Key factors that Influence ADC Therapeutics
Dr Jagath Reddy JUNUTULADr Jagath Reddy JUNUTULA
(GENENTECH, South San Francisco, United States)

Read more
ADMET Modelling: Where is it Worth the Effort?
Dr Richard LAWDr Richard LAW
(EVOTEC, Abingdon, United Kingdom)

Read more
Of Ionic Channels, Venom Toxins and Other Natural Substances ... and Diseases
Prof. Michel LAZDUNSKIProf. Michel LAZDUNSKI
(INSTITUT DE PHARMACOLOGIE MOLECULAIRE ET CELLULAIRE (IPMC), Nice, France)

Read more
Improving Compound Quality in Medicinal Chemistry
Dr Paul LEESONDr Paul LEESON
(ASTRAZENECA, Nuneaton, United Kingdom)

Read more
SOM230: A New Therapeutic Modality for Cushing’s Disease
Dr Ian LEWISDr Ian LEWIS
(NOVARTIS, Basel, Switzerland)

Read more
How Animal Venoms Help to Understand Pain: Acid-Sensing Ion Channels in the Pain Pathway
Dr Eric LINGUEGLIADr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

Read more
Developing New Tools for Cancer Diagnostics and Therapeutics: Fluorescent Peptide Biosensors of Cyclin-Dependent Kinases
Dr May MORRISDr May MORRIS
(CENTRE DE RECHERCHE EN BIOCHIMIE MACROMOLÉCULAIRE (CRBM) - CNRS, Montpellier, France)

Read more
Validation of Protein Kinases as Drug Targets in the African Trypanosome
Prof. Jeremy MOTTRAMProf. Jeremy MOTTRAM
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

Read more
All in Good Time, Exploiting Residence Time to Improve Fragment Based Drug Discovery
Dr James MURRAYDr James MURRAY
(VERNALIS, Cambridge, United Kingdom)

Read more
Ion Channel Drug Discovery: a Medicinal Chemistry Perspective
Dr Robert OWENDr Robert OWEN
(PFIZER NEUSENTIS, Cambridge, United Kingdom)

Read more
GLPG0974, a FFA2 Antagonist from Hit to Clinic
Dr Laurent SANIEREDr Laurent SANIERE
(GALAPAGOS, Romainville, France)

Read more
Discovery of Potent and Selective Inhibitors of the Cardiac Sodium/Calcium Exchanger (NCX-1)
Dr Hartmut SCHIROKDr Hartmut SCHIROK
(BAYER, Wuppertal, Germany)

Read more
Molecular Networks : Drug Action and Genome-Informed Medicine
Prof. Giulio SUPERTI-FURGAProf. Giulio SUPERTI-FURGA
(RESEARCH CENTER FOR MOLECULAR MEDICINE (CEMM), Vienna, Austria)

Read more
Drugs for Bad Bugs - Strategies to Address Infections by Multidrug-resistant Bacteria
Dr Jean-Philippe SURIVETDr Jean-Philippe SURIVET
(ACTELION, Allschwil, Switzerland)

Read more
Allosteric Modulation of the Chemokine Receptor CXCR3
Dr Nuska TSCHAMMERDr Nuska TSCHAMMER
(UNIVERSITY OF ERLANGEN-NÜRNBERG, Erlangen, Germany)

Read more
Drug Discovery for Diseases of the Developing World
Prof. Paul WYATTProf. Paul WYATT
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Read more

Organised by

With the support of

Major Sponsors

Sponsors

Media Partners

Copyright 2019 LD Organisation sprl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys